Literature DB >> 33908611

High prevalence of Cryptococcal antigenemia using a finger-prick lateral flow assay in individuals with advanced HIV disease in Santarém Municipality, Brazilian Amazon Basin.

João Guilherme Pontes Lima Assy1,2,3, Renato do Carmo Said1,2,3, Olivia Campos Pinheiro1,2,3, Alisson Dos Santos Brandão1,2,3, David R Boulware4, Francisco Oscar de Siqueira França3,5, José Ernesto Vidal6,7,8.   

Abstract

There is scarce information about HIV-related cryptococcosis in the Brazilian Amazon basin where laboratory infrastructure is limited. The serum cryptococcal antigen (CrAg) lateral flow assay (LFA) has simplified diagnosis of cryptococcosis and is recommended for screening in advanced HIV disease. We evaluated the prevalence of cryptococcal antigenemia using finger-prick CrAg LFA in the Brazilian Amazon basin. We enrolled a prospective cohort of outpatients and hospitalized individuals with advanced HIV disease at two centers in Santarém Municipality, Northern Brazil. All individuals were > 18 years old with advanced HIV disease, regardless of antiretroviral therapy (ART) status and with no prior or current history of confirmed cryptococcal meningitis. We tested CrAg LFA on finger-prick whole blood using an exact volume transfer pipette. From August 2018 to October 2019, 104 individuals were enrolled (outpatients 62 [60%] and hospitalized 42 [40%]). Median age was 38 years (interquartile range [IQR] 30-46), and 84 (81%) were male. Sixty-five (63%) individuals were ART-naïve. Prevalence of finger-prick CrAg LFA-positive was 10.6%; 95% CI, 5.4 to 18.1%. Prevalence of finger-prick CrAg LFA-positive among individuals without neurological symptoms was 6.0%; 95% CI, 1.7-14.6%. The number needed to test to detect one CrAg-positive individual was 9.4 persons (95% CI, 5.5-18.5). Prevalence of cryptococcal antigenemia using finger-prick whole blood CrAg LFA was high. Point-of-care approach was important for the diagnosis and screening of cryptococcosis in resource-limited settings. Screening and preemptive therapy strategy should be urgently implemented in individuals with advanced HIV disease in the Brazilian Amazon basin.
© The Author(s) 2021. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Entities:  

Keywords:  Brazil; Cryptococcosis; HIV/AIDS, diagnosis; lateral flow assay; prevalence

Mesh:

Substances:

Year:  2021        PMID: 33908611      PMCID: PMC8604274          DOI: 10.1093/mmy/myab021

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  28 in total

1.  National coverage of reflex cryptococcal antigen screening: A milestone achievement in the care of persons with advanced HIV disease.

Authors:  N P Govender; D K Glencross
Journal:  S Afr Med J       Date:  2018-06-26

2.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

Review 3.  Cryptococcosis in the Amazon: A current overview and future perspectives.

Authors:  Miguel Corrêa Pinheiro; Danielle Saraiva Tuma Dos Reis; Mioni Thieli Figueiredo Magalhães de Brito; Juarez Antonio Simões Quaresma
Journal:  Acta Trop       Date:  2019-06-08       Impact factor: 3.112

4.  Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

Authors:  Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware
Journal:  Lancet Infect Dis       Date:  2017-05-05       Impact factor: 25.071

5.  Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus-Infected Adults in Ethiopia.

Authors:  Admasu Tenna Mamuye; Ethan Bornstein; Obsie Temesgen; Henry M Blumberg; Russell R Kempker
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

6.  Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings.

Authors:  Christian Obirikorang; Lawrence Quaye; Isaac Acheampong
Journal:  BMC Infect Dis       Date:  2012-06-07       Impact factor: 3.090

7.  Performance of non-laboratory staff for diagnostic testing and specimen collection in HIV programs: A systematic review and meta-analysis.

Authors:  Lara Vojnov; Miriam Taegtmeyer; Caroline Boeke; Jessica Markby; Lindsay Harris; Meg Doherty; Trevor Peter; Nathan Ford
Journal:  PLoS One       Date:  2019-05-02       Impact factor: 3.240

8.  Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil.

Authors:  Moara Alves Santa Bárbara Borges; João Alves de Araújo Filho; Bruno de Jesus Silva Oliveira; Isabela Silvério Moreira; Vanessa Valadares de Paula; Angélica Lima de Bastos; Renata de Bastos Ascenço Soares; Marília Dalva Turchi
Journal:  PLoS One       Date:  2019-07-25       Impact factor: 3.240

9.  Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.

Authors:  Joseph N Jarvis; Thomas S Harrison; Stephen D Lawn; Graeme Meintjes; Robin Wood; Susan Cleary
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

10.  CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.

Authors:  Nathan Ford; Zara Shubber; Joseph N Jarvis; Tom Chiller; Greg Greene; Chantal Migone; Marco Vitoria; Meg Doherty; Graeme Meintjes
Journal:  Clin Infect Dis       Date:  2018-03-04       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.